Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCPH shares.
View DCPH analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12 month target prices for Deciphera Pharmaceuticals' shares. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they predict the company's share price to reach $22.22 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of 2023. Since then, DCPH shares have decreased by 10.0% and is now trading at $14.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our DCPH earnings forecast.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings data on Tuesday, February, 7th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.03. The firm had revenue of $36.40 million for the quarter, compared to analysts' expectations of $35.88 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 51.42% and a negative net margin of 133.49%. The company's quarterly revenue was up 50.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.51) EPS.

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

Deciphera Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Tuesday, January, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$36.00 million, compared to the consensus revenue estimate of $34.83 million.

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.81%), Braidwell LP (4.31%), Avidity Partners Management LP (1.48%), Dimensional Fund Advisors LP (1.59%), Assenagon Asset Management S.A. (1.50%) and Geode Capital Management LLC (1.20%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends.

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $14.75.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.12 billion and generates $134.04 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The company employs 280 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.